View ValuationGrifols 将来の成長Future 基準チェック /36Grifols利益と収益がそれぞれ年間20.4%と5.6%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に11.7% 21.4%なると予測されています。主要情報20.4%収益成長率21.44%EPS成長率Biotechs 収益成長21.1%収益成長率5.6%将来の株主資本利益率11.66%アナリストカバレッジGood最終更新日14 May 2026今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • May 18Grifols, S.A., Annual General Meeting, Jun 17, 2026Grifols, S.A., Annual General Meeting, Jun 17, 2026. Location: parque empresarial can sant joan, avinguda de la generalitat, sant cugat del valles, barcelona., SpainReported Earnings • May 11First quarter 2026 earnings releasedFirst quarter 2026 results: EPS: €0.11. Revenue: €1.70b (down 4.8% from 1Q 2025). Net income: €73.0m (up 22% from 1Q 2025). Profit margin: 4.3% (up from 3.3% in 1Q 2025). Revenue is forecast to grow 5.7% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 77% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.お知らせ • Feb 25Grifols, S.A. to Report Fiscal Year 2025 Results on Feb 26, 2026Grifols, S.A. announced that they will report fiscal year 2025 results at 5:35 PM, Central European Standard Time on Feb 26, 2026Valuation Update With 7 Day Price Move • Feb 03Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €9.98, the stock trades at a forward P/E ratio of 14x. Average trailing P/E is 17x in the Biotechs industry in Europe. Total loss to shareholders of 25% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €18.75 per share.お知らせ • Jan 09Grifols, S.A. Announces Board Changes, Effective January 1, 2026Grifols, S.A. Board of Directors resolved to unanimously approve, with effect from January 1, 2026, the appointment of Ms. Laura de la Cruz Galán as the new Secretary non-member of the Board of Directors, replacing Mrs. Núria Martín Barnés, and the appointment of Mrs. Núria Martín Barnés as the new Vice-secretary non-member of the Board of Directors, replacing Ms. Laura de la Cruz Galán.Valuation Update With 7 Day Price Move • Dec 18Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €11.85, the stock trades at a forward P/E ratio of 14x. Average trailing P/E is 17x in the Biotechs industry in Europe. Total returns to shareholders of 12% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €21.17 per share.New Risk • Dec 14New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 2.8x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.8x net interest cover). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (6.7% average weekly change).New Risk • Nov 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 5.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (5.9% average weekly change).Valuation Update With 7 Day Price Move • Nov 24Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to €9.33, the stock trades at a forward P/E ratio of 13x. Average trailing P/E is 18x in the Biotechs industry in Europe. Total loss to shareholders of 7.8% over the past three years.Upcoming Dividend • Aug 04Upcoming dividend of €0.12 per shareEligible shareholders must have bought the stock before 11 August 2025. Payment date: 13 August 2025. The company last paid an ordinary dividend in October 2014. The average dividend yield among industry peers is 2.1%.New Risk • Jul 31New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 3.0x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (3.0x net interest cover). Minor Risks Share price has been volatile over the past 3 months (5.5% average weekly change). Large one-off items impacting financial results.Reported Earnings • Jul 30Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: €1.89b (up 4.0% from 2Q 2024). Net income: €117.1m (up €102.2m from 2Q 2024). Profit margin: 6.2% (up from 0.8% in 2Q 2024). Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Europe.Board Change • Jun 25High number of new directorsIndependent Director Pascal Ravery was the last director to join the board, commencing their role in 2024.お知らせ • May 12Grifols, S.A. to Report Q1, 2025 Results on May 12, 2025Grifols, S.A. announced that they will report Q1, 2025 results on May 12, 2025お知らせ • May 03Grifols, S.A., Annual General Meeting, Jun 04, 2025Grifols, S.A., Annual General Meeting, Jun 04, 2025. Location: parque empresarial can sant joan, avinguda de la generalitat, 152-158, 08174 sant cugat del valles, barcelona SpainValuation Update With 7 Day Price Move • Apr 04Investor sentiment deteriorates as stock falls 21%After last week's 21% share price decline to €8.18, the stock trades at a forward P/E ratio of 12x. Average trailing P/E is 21x in the Biotechs industry in Europe. Total loss to shareholders of 50% over the past three years.業績と収益の成長予測BIT:1GRF - アナリストの将来予測と過去の財務データ ( )EUR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20288,6958569941,434812/31/20278,2067048041,1751112/31/20267,68951150683093/31/20267,4384155961,021N/A12/31/20257,5244026241,047N/A9/30/20257,5183736991,131N/A6/30/20257,4462976961,105N/A3/31/20257,3721958041,203N/A12/31/20247,212157530902N/A9/30/20247,006161209527N/A6/30/20246,81114973387N/A3/31/20246,656189-187105N/A12/31/20236,59242-93217N/A9/30/20236,53523-217119N/A6/30/20236,479-5-496-123N/A3/31/20236,35847-485-107N/A1/1/20236,064185-394-1N/A9/30/20225,549149-27250N/A6/30/20225,20766-36289N/A3/31/20225,016112137454N/A12/31/20214,933189282597N/A9/30/20215,044361400727N/A6/30/20215,199667597909N/A3/31/20215,2315628471,183N/A12/31/20205,3406197481,110N/A9/30/20205,3926876631,081N/A6/30/20205,353557551964N/A3/31/20205,235697425842N/A12/31/20195,099625N/A569N/A9/30/20194,961552N/A668N/A6/30/20194,790565N/A634N/A3/31/20194,620568N/A477N/A12/31/20184,487597N/A737N/A9/30/20184,332699N/A680N/A6/30/20184,246704N/A712N/A3/31/20184,279672N/A789N/A12/31/20174,318663N/A842N/A9/30/20174,348571N/A751N/A6/30/20174,291559N/A765N/A3/31/20174,153554N/A640N/A12/31/20164,050545N/A553N/A9/30/20164,014537N/A683N/A6/30/20163,986535N/A652N/A3/31/20163,985529N/A767N/A12/31/20153,935532N/A743N/A9/30/20153,789533N/A755N/A6/30/20153,645507N/A836N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 1GRFの予測収益成長率 (年間20.4% ) は 貯蓄率 ( 3.3% ) を上回っています。収益対市場: 1GRFの収益 ( 20.4% ) はItalian市場 ( 11% ) よりも速いペースで成長すると予測されています。高成長収益: 1GRFの収益は今後 3 年間で 大幅に 増加すると予想されています。収益対市場: 1GRFの収益 ( 5.6% ) Italian市場 ( 5.7% ) よりも低い成長が予測されています。高い収益成長: 1GRFの収益 ( 5.6% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 1GRFの 自己資本利益率 は、3年後には低くなると予測されています ( 11.7 %)。成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/20 09:16終値2026/05/20 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Grifols, S.A. 11 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。32 アナリスト機関null nullBanco de Sabadell. S.A.Luis ArredondoBanco de Sabadell. S.A.Jaime EscribanoBanco Santander29 その他のアナリストを表示
お知らせ • May 18Grifols, S.A., Annual General Meeting, Jun 17, 2026Grifols, S.A., Annual General Meeting, Jun 17, 2026. Location: parque empresarial can sant joan, avinguda de la generalitat, sant cugat del valles, barcelona., Spain
Reported Earnings • May 11First quarter 2026 earnings releasedFirst quarter 2026 results: EPS: €0.11. Revenue: €1.70b (down 4.8% from 1Q 2025). Net income: €73.0m (up 22% from 1Q 2025). Profit margin: 4.3% (up from 3.3% in 1Q 2025). Revenue is forecast to grow 5.7% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 77% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.
お知らせ • Feb 25Grifols, S.A. to Report Fiscal Year 2025 Results on Feb 26, 2026Grifols, S.A. announced that they will report fiscal year 2025 results at 5:35 PM, Central European Standard Time on Feb 26, 2026
Valuation Update With 7 Day Price Move • Feb 03Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €9.98, the stock trades at a forward P/E ratio of 14x. Average trailing P/E is 17x in the Biotechs industry in Europe. Total loss to shareholders of 25% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €18.75 per share.
お知らせ • Jan 09Grifols, S.A. Announces Board Changes, Effective January 1, 2026Grifols, S.A. Board of Directors resolved to unanimously approve, with effect from January 1, 2026, the appointment of Ms. Laura de la Cruz Galán as the new Secretary non-member of the Board of Directors, replacing Mrs. Núria Martín Barnés, and the appointment of Mrs. Núria Martín Barnés as the new Vice-secretary non-member of the Board of Directors, replacing Ms. Laura de la Cruz Galán.
Valuation Update With 7 Day Price Move • Dec 18Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €11.85, the stock trades at a forward P/E ratio of 14x. Average trailing P/E is 17x in the Biotechs industry in Europe. Total returns to shareholders of 12% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €21.17 per share.
New Risk • Dec 14New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 2.8x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.8x net interest cover). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (6.7% average weekly change).
New Risk • Nov 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 5.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (5.9% average weekly change).
Valuation Update With 7 Day Price Move • Nov 24Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to €9.33, the stock trades at a forward P/E ratio of 13x. Average trailing P/E is 18x in the Biotechs industry in Europe. Total loss to shareholders of 7.8% over the past three years.
Upcoming Dividend • Aug 04Upcoming dividend of €0.12 per shareEligible shareholders must have bought the stock before 11 August 2025. Payment date: 13 August 2025. The company last paid an ordinary dividend in October 2014. The average dividend yield among industry peers is 2.1%.
New Risk • Jul 31New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 3.0x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (3.0x net interest cover). Minor Risks Share price has been volatile over the past 3 months (5.5% average weekly change). Large one-off items impacting financial results.
Reported Earnings • Jul 30Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: €1.89b (up 4.0% from 2Q 2024). Net income: €117.1m (up €102.2m from 2Q 2024). Profit margin: 6.2% (up from 0.8% in 2Q 2024). Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Europe.
Board Change • Jun 25High number of new directorsIndependent Director Pascal Ravery was the last director to join the board, commencing their role in 2024.
お知らせ • May 12Grifols, S.A. to Report Q1, 2025 Results on May 12, 2025Grifols, S.A. announced that they will report Q1, 2025 results on May 12, 2025
お知らせ • May 03Grifols, S.A., Annual General Meeting, Jun 04, 2025Grifols, S.A., Annual General Meeting, Jun 04, 2025. Location: parque empresarial can sant joan, avinguda de la generalitat, 152-158, 08174 sant cugat del valles, barcelona Spain
Valuation Update With 7 Day Price Move • Apr 04Investor sentiment deteriorates as stock falls 21%After last week's 21% share price decline to €8.18, the stock trades at a forward P/E ratio of 12x. Average trailing P/E is 21x in the Biotechs industry in Europe. Total loss to shareholders of 50% over the past three years.